Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Sarcoma 1Lymphoma 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Acetates × Lymphoid × Clear all
NCT04190433 2023-05-24

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Mayo Clinic

Phase 2 Withdrawn
BreastLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡